Abstract
Ofatumumab is an antibody against a protein called CD20, which is found on the surface of certain types of immune cells called B-cells, that was approved to treat relapsing Multiple Sclerosis (MS) in adults with active disease. Our objective was to estimate the cost effectiveness of ofatumumab versus ocrelizumab in adult patients with active disease, defined by clinical or imaging characteristics, without prior treatment (naïve patients, 1st line).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.